Screener / SEC EDGAR /CIK 0001520262 /10-K filed Feb 25, 2026, compared with Feb 12, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Alkermes plc. ALKS

Compare with peers Embed
What it said it expected, against what it reported

4 targets with a reported result

Releases of the last 3 years
Above the range 0 above the last range given
Within the range 4 of 4 range targets
Below the range 0 below the last range given

The numbers ALKS said it expected, in its earnings releases, next to what it then reported for the same period.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
EBITDA (company-defined)
Fiscal 2026
Given $370.00M to $410.00M release Feb 25, 2026
Kept $370.00M to $410.00M release May 5, 2026
Kept $370.00M to $410.00M release Jul 28, 2026
– No standard number
The company's words
(In millions) 2026 Expectations … Adjusted EBITDA $370 – $410 release Feb 25, 2026
Updated 2026 Previous 2026 Expectations(provided Expectations(provided May 5, (In millions) Feb. 25, 2026) 2026) … Adjusted EBITDA e $370 – $410 release May 5, 2026
Previous 2026 Updated 2026 Expectations(provided Expectations(provided May 5, July 28, (In millions) 2026) 2026) … Adjusted EBITDA f $370 – $410 release Jul 28, 2026
Revenue
Fiscal 2026
Given $1.73B to $1.84B release Feb 25, 2026
Kept $1.73B to $1.84B release May 5, 2026
Kept $1.73B to $1.84B release Jul 28, 2026
– Not reported yet
The company's words
(In millions) 2026 Expectations … Total Revenues $1,730 – $1,840 release Feb 25, 2026
Updated 2026 Previous 2026 Expectations(provided Expectations(provided May 5, (In millions) Feb. 25, 2026) 2026) … Total Revenues $1,730 – $1,840 release May 5, 2026
Previous 2026 Updated 2026 Expectations(provided Expectations(provided May 5, July 28, (In millions) 2026) 2026) … Total Revenues $1,730 – $1,840 release Jul 28, 2026
EBITDA (company-defined)
Fiscal 2025 (ended Dec 31, 2025)
Given $215.00M to $245.00M release Feb 12, 2025
Raised $270.00M to $290.00M release Oct 28, 2025
– No standard number
The company's words
In millions 2025 Expectations … EBITDA $215 – $245 release Feb 12, 2025
Previous 2025 Updated 2025 Expectations(provided Expectations(provided (In millions) Feb. 12, 2025) Oct. 28, 2025) … EBITDA b $270 – $290 release Oct 28, 2025
Net income
Fiscal 2025 (ended Dec 31, 2025)
Given $175.00M to $205.00M release Feb 12, 2025
Raised $230.00M to $250.00M release Oct 28, 2025
$241.66M
10-K filed 2026-02-25
Within the range
The company's words
In millions 2025 Expectations … GAAP Net Income a $175 – $205 release Feb 12, 2025
Previous 2025 Updated 2025 Expectations(provided Expectations(provided (In millions) Feb. 12, 2025) Oct. 28, 2025) … GAAP Net Income a $230 – $250 release Oct 28, 2025
Revenue
Fiscal 2025 (ended Dec 31, 2025)
Given $1.34B to $1.43B release Feb 12, 2025
Lowered $265.00M to $275.00M release Oct 22, 2025
Raised $1.43B to $1.49B release Oct 28, 2025
$1.48B
10-K filed 2026-02-25
Within the range
The company's words
In millions 2025 Expectations … Total Revenues $1,340 – $1,430 release Feb 12, 2025
With net revenues of $265 – $275 million expected in 2025 and an estimated population of >50,000 oxybate- eligible narcolepsy patients in the United States, LUMRYZ ™has been on a robust growth trajectory, with significant opportunity for growth ahead. release Oct 22, 2025
Previous 2025 Updated 2025 Expectations(provided Expectations(provided (In millions) Feb. 12, 2025) Oct. 28, 2025) … Total Revenues $1,430 – $1,490 release Oct 28, 2025
EBITDA (company-defined)
Fiscal 2024 (ended Dec 31, 2024)
Given $445.00M to $485.00M release Feb 15, 2024
– No standard number
The company's words
In millions 2024 Expectations … EBITDA $445 – $485 release Feb 15, 2024
Net income
Fiscal 2024 (ended Dec 31, 2024)
Given $350.00M to $390.00M release Feb 15, 2024
$367.07M
10-K filed 2025-02-12
Within the range
The company's words
In millions 2024 Expectations … GAAP Net Income b $350 – $390 release Feb 15, 2024
Net income (company-defined)
Fiscal 2024 (ended Dec 31, 2024)
Given $465.00M to $505.00M release Feb 15, 2024
– No standard number
The company's words
In millions 2024 Expectations … Non-GAAP Net Income b $465 – $505 release Feb 15, 2024
Revenue
Fiscal 2024 (ended Dec 31, 2024)
Given $1.50B to $1.60B release Feb 15, 2024
$1.56B
10-K filed 2025-02-12
Within the range
The company's words
In millions 2024 Expectations … Total Revenues a $1,500 – $1,600 release Feb 15, 2024

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (15 releases since 2024-02-15), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ALKS/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.